Madrigal Pharmaceuticals, Inc. (MDGL)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS5588681057
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Madrigal Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:07. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 18 Feb 2027 08:00 | 1.92 | — | — | Upcoming |
| 03 Nov 2026 07:00 | -0.87 | 1.83 | +309.6% | Beat |
| 30 Jul 2026 07:00 | -2.23 | -1.99 | +10.8% | Beat |
| 06 May 2026 07:00 | -4.14 | -1.38 | +66.7% | Beat |
| 19 Feb 2026 07:00 | -0.88 | -2.57 | -192.2% | Miss |
| 04 Nov 2025 07:00 | -1.99 | -4.96 | -148.8% | Miss |
| 05 Aug 2025 07:00 | -3.53 | -1.90 | +46.2% | Beat |
| 01 May 2025 07:00 | -3.79 | -3.32 | +12.4% | Beat |
| 26 Feb 2025 07:00 | -4.12 | -2.71 | +34.3% | Beat |
| 31 Oct 2024 07:00 | -6.91 | -4.92 | +28.8% | Beat |
| 07 Aug 2024 07:00 | -7.66 | -7.10 | +7.3% | Beat |
| 07 May 2024 09:00 | -6.39 | -7.38 | -15.4% | Miss |
| 28 Feb 2024 06:00 | -5.34 | -5.68 | -6.3% | Miss |
| 06 Nov 2023 06:00 | -4.93 | -5.34 | -8.4% | Miss |
| 08 Aug 2023 08:00 | -4.54 | -4.69 | -3.3% | Miss |
| 09 May 2023 06:00 | -4.78 | -4.23 | +11.6% | Beat |
| 23 Feb 2023 08:00 | -4.61 | -4.98 | -8.0% | Miss |
| 03 Nov 2022 08:00 | -4.18 | -4.75 | -13.7% | Miss |
| 04 Aug 2022 06:00 | -3.64 | -4.14 | -13.6% | Miss |
| 09 May 2022 06:00 | -3.54 | -3.36 | +5.1% | Beat |
| 24 Feb 2022 13:00 | -3.91 | -3.79 | +3.0% | Beat |
| 04 Nov 2021 06:00 | -3.85 | -3.79 | +1.6% | Beat |
| 05 Aug 2021 06:00 | -3.54 | -3.72 | -5.1% | Miss |
| 06 May 2021 06:00 | -3.94 | -3.32 | +15.7% | Beat |
| 25 Feb 2021 11:00 | -3.90 | -3.82 | +2.1% | Beat |
| 05 Nov 2020 06:00 | -3.30 | -3.75 | -13.6% | Miss |
| 06 Aug 2020 06:00 | -2.43 | -3.18 | -30.6% | Miss |
| 07 May 2020 06:00 | -1.95 | -2.34 | -20.3% | Miss |
| 26 Feb 2020 06:00 | -1.67 | -1.80 | -7.7% | Miss |
| 06 Nov 2019 06:00 | -1.42 | -1.39 | +2.1% | Beat |
| 07 Aug 2019 06:00 | -1.22 | -1.28 | -4.8% | Miss |
| 08 May 2019 06:00 | -0.97 | -0.98 | -1.4% | Miss |
| 27 Feb 2019 06:00 | -0.74 | -0.76 | -2.1% | Miss |
| 06 Nov 2018 06:00 | -0.53 | -0.56 | -6.2% | Miss |
| 07 Aug 2018 06:00 | -0.62 | -0.45 | +27.8% | Beat |
| 08 May 2018 06:00 | -0.77 | -0.45 | +41.5% | Beat |
| 13 Mar 2018 06:00 | -0.70 | -0.67 | +4.0% | Beat |
| 09 Nov 2017 06:00 | -0.79 | -0.68 | +13.6% | Beat |
| 10 Aug 2017 06:00 | -0.60 | -0.69 | -15.0% | Miss |
| 11 May 2017 16:00 | -0.87 | -0.50 | +42.5% | Beat |
| 31 Mar 2017 16:00 | -1.39 | -2.83 | -103.6% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 958.4M | +432.1% | -288.3M | -30.1% | -12.85 | +41.3% | -193M |
| 2024 | 180.1M | — | -465.9M | -258.6% | -21.90 | -9.6% | -462M |
| 2023 | 0 | — | -373.6M | — | -19.99 | -16.0% | -325.7M |
| 2022 | 0 | — | -295.4M | — | -17.23 | — | -225.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 12 Nov 2026 In progress | 411.50 | 443.30 | 402.00 | 425.21 | +6.40% | 1,718,100 | |
| 02 Nov 2026 – 06 Nov 2026 | 430.04 | 482.73 | 353.54 | 399.63 | -7.14% | 6,732,900 | |
| 26 Oct 2026 – 30 Oct 2026 | 435.66 | 445.66 | 425.00 | 430.36 | -0.89% | 1,302,500 | |
| 19 Oct 2026 – 23 Oct 2026 | 450.64 | 481.87 | 433.31 | 434.24 | -3.45% | 1,456,900 | |
| 12 Oct 2026 – 16 Oct 2026 | 471.75 | 478.85 | 446.61 | 449.74 | -4.67% | 1,742,800 | |
| 05 Oct 2026 – 09 Oct 2026 | 501.89 | 505.00 | 466.06 | 471.75 | -5.54% | 1,520,400 | |
| 28 Sep 2026 – 02 Oct 2026 | 515.10 | 525.00 | 491.05 | 499.40 | -3.32% | 1,304,400 | |
| 21 Sep 2026 – 25 Sep 2026 | 536.04 | 536.04 | 502.63 | 516.56 | -2.81% | 1,140,800 | |
| 14 Sep 2026 – 18 Sep 2026 | 540.00 | 541.35 | 513.36 | 531.52 | -0.56% | 1,198,300 | |
| 08 Sep 2026 – 11 Sep 2026 | 534.17 | 549.97 | 519.10 | 534.49 | -1.22% | 893,500 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth (opens in a new tab) Zacks · 10 Nov 2026 13:13
- Madrigal’s MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales (opens in a new tab) Stocktwits · 05 Nov 2026 17:25
- Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra (opens in a new tab) 05 Nov 2026 15:00
- Madrigal Pharmaceuticals Announces Data From Its Rezdiffra Trials Demonstrated 55% Participants Achieved Over 25% Improvement In Liver Stiffness, 48% Patients Reports Over 30% Improvement At 12 Months (opens in a new tab) Benzinga · 05 Nov 2026 11:08
- Madrigal Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 05 Nov 2026 02:07
- First Profitable Quarter Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL) (opens in a new tab) Simply Wall St. · 04 Nov 2026 23:17
- Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633 (opens in a new tab) Benzinga · 04 Nov 2026 19:44
- Madrigal Pharmaceuticals (MDGL) Stock May Be Below Fair Value Despite First Profit (opens in a new tab) Simply Wall St. · 04 Nov 2026 18:11
- Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743 (opens in a new tab) Benzinga · 04 Nov 2026 12:45
- Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To Buy (opens in a new tab) SeekingAlpha · 04 Nov 2026 11:07
- Madrigal Pharmaceuticals (MDGL) Turns Profitable, Is The 42% Undervaluation Case Still Convincing? (opens in a new tab) Simply Wall St. · 04 Nov 2026 03:22
- Madrigal Pharmaceuticals Inc (MDGL) Q3 2026 Earnings Call Highlights: First Profitable Quarter ... (opens in a new tab) GuruFocus.com · 03 Nov 2026 21:05
- Madrigal (MDGL) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 20:38
- MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside (opens in a new tab) Stocktwits · 03 Nov 2026 20:15
- Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 19:25
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 433.03 USD
- Market cap
- 9.9B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 3.1 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.6 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -13.5× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 37.93× | Weak | 14.16× |
| Price / book | 15.75× | Weak | 3.5× |
| Price / sales | 6.92× | Weak | 3.33× |
| EV / EBITDA | -61.35× | Weak | 11.19× |
| Free cash flow yield | -1.1% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 91% | Good | 54.9% |
| Operating margin | -10.7% | Weak | 5.8% |
| Net margin | -10.9% | Weak | 1.2% |
| Return on equity | -24.8% | Weak | 4.4% |
| Return on assets | -6.8% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.56× | Good | 0.4× |
| Interest cover | -13.45× | Weak | 2.17× |
| Current ratio | 3.05× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow MDGL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.